Migraine – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (Prophylaxis) US
Migraine is a neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns focuses specifically on the prophylactic treatment of migraine, aimed at preemptively reducing the frequency, severity, and duration of future migraine attacks and, in turn, reducing patients’ level of disability and potentially increasing the responsiveness of breakthrough migraine attacks to acute treatment. Although generic AEDs, antidepressants, and beta blockers dominate the first three lines of therapy, our report provides insight on both the market-leading classes and the uptake of newer-to-market classes, such as CGRP monoclonal antibodies and the CGRP-targeted oral therapy Qulipta (AbbVie). Please note that we do not include Pfizer’s Nurtec ODT in our main analysis as we cannot easily parse out acute use of the drug from its prophylactic use.
Questions answered
- What patient shares do key therapies and brands garner in the prophylactic treatment of migraine by line of therapy in newly diagnosed patients? What are the quarterly trends in prescribing of prophylactic therapies among recently treated and newly diagnosed migraine patients?
- How have CGRP-targeted therapies been integrated into the prophylactic treatment algorithm, and what is their source of business?
- What percentage of migraine patients receive prophylactic drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of prophylactic therapy within two years of diagnosis?
- What percentage of migraine patients are treated with monotherapy versus combination prophylactic therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates for prophylactic therapies among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States.
Key companies: Amgen, Novartis, Eli Lilly, Teva, Lundbeck, and AbbVie.
Key drugs: Aimovig, Emgality, Ajovy, Vyepti, Qulipta, Botox, topiramate IR, topiramate XR, Trokendi XR, amitriptyline, propranolol.
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Table of contents
- Migraine - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (Prophylaxis) US
- Treatment Algorithms CDA Migraine (Prophylaxis) US May 2023
- Treatment Algorithms CDA Migraine (Prophylaxis) 2023 Dashboard
Ankita Sharma, M.B.A., Manager, Healthcare Research & Data Analytics, CNS/Ophthalmology Disorders. Ankita’s focus is the epilepsy market. Prior to joining the company, she was a knowledge management manager at ZS Associates. She received her M.B.A. in hospital and healthcare administration from Symbiosis International University in India.
Andrea S. Witt, Ph.D., is Director of the Central Nervous System and Ophthalmology Disorders Portfolio at Clarivate, where she oversees a team of Business Insights Analysts and Senior Directors responsible for market research encompassing Neurology, Psychiatry, Pain, and Ophthalmology.
Her interests beyond specific CNS indications included the market potential for neuroprotectants and the impact of biomarkers on CNS markets. Dr. Witt’s research, analysis, and commentaries have appeared in Barron’s, Pharmaceutical Executive, PharmaVoice, Nature Medicine, and CNBC. Dr. Witt’s previous experience includes 10 years of scientific research conducted on neurodegenerative disorders at Harvard Medical School/Brigham and Women’s Hospital, Duke University, and the University of Texas-Southwestern Medical Center, where she earned her Ph.D. degree.